Resverlogix Corp.
4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
403 254 9252
http://www.resverlogix.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 25
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. | 505.2k | N/A | N/A |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer | 281.8k | N/A | N/A |
| Mr. Kenneth Eugene Lebioda BA | Sr. VP of Bus. & Corp. Devel. | 264.6k | N/A | N/A |
| Dr. Michael Sweeney | Sr. VP of Clinical Devel. | 525.29k | N/A | 1961 |
| Dr. Ewelina Kulikowski | Sr. VP of R&D | 250k | N/A | N/A |
| Dr. Norman C.W. Wong B.Sc., FRCPC, M.Sc., B.Sc (Hon), M.Sc, M.D., FRCP( | Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board | N/A | N/A | N/A |
| Mr. Paul Moon | VP of Investor Relations & Communications | N/A | N/A | N/A |
| Sarah Zapotichny | Director of Investor Relations & Corp. Communications | N/A | N/A | N/A |
| Dr. Jan O. Johansson | Sr. VP of Medical Affairs | N/A | N/A | N/A |
Description
Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.
Corporate Governance
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
